26 MAIN STREET, SUITE 101, CHATHAM, NJ
8-K
Reports First Quarter 2026 Financial Results and Operational Highlights
Shareholders Approve 2026 Stock Incentive Plan at Annual Meeting
Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Tonix Pharmaceuticals Reports Q1 2026 Financial Results and Cash Position
Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
Q1
Q3
Q2
FY 2024
Notice of Late Filing for Quarterly Report
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload